JP2017515909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515909A5 JP2017515909A5 JP2017512461A JP2017512461A JP2017515909A5 JP 2017515909 A5 JP2017515909 A5 JP 2017515909A5 JP 2017512461 A JP2017512461 A JP 2017512461A JP 2017512461 A JP2017512461 A JP 2017512461A JP 2017515909 A5 JP2017515909 A5 JP 2017515909A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- formulation according
- seq
- concentration
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461994427P | 2014-05-16 | 2014-05-16 | |
| US61/994,427 | 2014-05-16 | ||
| US201462093734P | 2014-12-18 | 2014-12-18 | |
| US62/093,734 | 2014-12-18 | ||
| US201462095181P | 2014-12-22 | 2014-12-22 | |
| US62/095,181 | 2014-12-22 | ||
| PCT/IB2015/053602 WO2015173782A1 (en) | 2014-05-16 | 2015-05-15 | Antibody formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035298A Division JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515909A JP2017515909A (ja) | 2017-06-15 |
| JP2017515909A5 true JP2017515909A5 (https=) | 2018-06-28 |
| JP6707528B2 JP6707528B2 (ja) | 2020-06-10 |
Family
ID=53200250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512461A Active JP6707528B2 (ja) | 2014-05-16 | 2015-05-15 | 抗体処方物 |
| JP2020035298A Active JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035298A Active JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10556009B2 (https=) |
| EP (3) | EP3715371A1 (https=) |
| JP (2) | JP6707528B2 (https=) |
| KR (2) | KR20170005099A (https=) |
| CN (1) | CN106661111A (https=) |
| AU (1) | AU2015260758B2 (https=) |
| BR (1) | BR112016026811A2 (https=) |
| CA (1) | CA2949212C (https=) |
| DK (1) | DK3143047T3 (https=) |
| ES (1) | ES2927990T3 (https=) |
| IL (1) | IL248802B (https=) |
| MX (1) | MX381232B (https=) |
| MY (1) | MY185802A (https=) |
| SG (1) | SG11201609622PA (https=) |
| TW (1) | TWI694836B (https=) |
| WO (1) | WO2015173782A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| AU2015335743B2 (en) | 2014-10-23 | 2020-12-24 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| AU2017305856B2 (en) * | 2016-08-05 | 2024-09-12 | Csl Behring Gmbh | Pharmaceutical formulations of C1 esterase inhibitor |
| CN110088132B (zh) | 2016-08-17 | 2020-10-27 | 康姆普根有限公司 | 抗tigit抗体，抗pvrig抗体及其组合 |
| JP7377596B2 (ja) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| JP7398958B2 (ja) * | 2017-04-11 | 2023-12-15 | キニクサ ファーマシューティカルズ， リミテッド | 安定的抗ｏｓｍｒ抗体製剤 |
| BR112019023737A2 (pt) * | 2017-05-16 | 2020-05-26 | Octapharma Ag | Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea |
| AU2019254483B2 (en) * | 2018-04-16 | 2025-02-27 | Merck Patent Gmbh | Viscosity reduction of highly concentrated protein formulations |
| AU2019388808A1 (en) * | 2018-11-29 | 2021-06-17 | Harbour Biomed Therapeutics Limited | Anti-PD-L1 antibody preparation |
| KR20210145187A (ko) * | 2019-03-29 | 2021-12-01 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도 |
| KR20220041881A (ko) * | 2019-07-29 | 2022-04-01 | 컴퓨젠 엘티디. | 항-pvrig 항체 제제 및 이의 용도 |
| JP2023501781A (ja) * | 2019-11-06 | 2023-01-19 | ノバルティス アーゲー | シェーグレン症候群の処置 |
| CN113546252A (zh) * | 2020-04-24 | 2021-10-26 | 上海君实生物医药科技股份有限公司 | 抗pcsk9抗体的药物递送装置 |
| MX2022013400A (es) | 2020-04-24 | 2023-01-04 | King S College London | Composicion que comprende un anticuerpo ige. |
| GB202006093D0 (en) | 2020-04-24 | 2020-06-10 | King S College London | Composition |
| US20230220092A1 (en) * | 2020-06-12 | 2023-07-13 | GlaxSmithKline Intellectual Property Management Limited | Anti-Blys Antibody for Treating Proteinuric Kidney Disease |
| JP2023549872A (ja) | 2020-11-18 | 2023-11-29 | アストラゼネカ・アクチエボラーグ | ステロイド節約 |
| JP2024514077A (ja) | 2021-03-31 | 2024-03-28 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 切断したｔａｃｉポリペプチド及びその融合タンパク質並びに使用 |
| WO2022223028A1 (zh) * | 2021-04-23 | 2022-10-27 | 上海君实生物医药科技股份有限公司 | 抗BLyS抗体、其药物组合物及其用途 |
| WO2022263551A1 (en) * | 2021-06-17 | 2022-12-22 | Glaxosmithkline Intellectual Property Limited | Anti-baff antibodies for use in a method of treatment of long covid and/or post-acute sequelae sars-cov-2 infection (pasc) |
| CA3226744A1 (en) | 2021-07-27 | 2023-02-02 | Astrazeneca Ab | Treatment of lupus |
| CA3239182A1 (en) * | 2022-05-23 | 2023-11-30 | Zhipeng SU | Stable antibody preparation |
| WO2024027793A1 (en) * | 2022-08-05 | 2024-02-08 | I-Mab Biopharma (Hangzhou) Co., Ltd. | Bispecific antibodies targeting ifnar1 and blys |
| JP2026510999A (ja) | 2023-03-21 | 2026-04-10 | バイオグラフ ５５，インク． | Ｃｄ１９／ｃｄ３８多重特異性抗体 |
| CN118255895B (zh) * | 2024-04-30 | 2024-10-29 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 抗BAFF和hIL21双特异性抗体及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| CA2763913C (en) | 2001-08-10 | 2014-10-28 | Aberdeen University | Antigen binding domains |
| AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| JP5290489B2 (ja) * | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｉｇｇ抗体の安定な液体医薬製剤 |
| CA2542777C (en) * | 2003-10-23 | 2016-02-02 | Chiron Corporation | Stabilised compositions |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| EA015860B1 (ru) * | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| US20110311548A1 (en) * | 2010-06-18 | 2011-12-22 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system |
| US9458240B2 (en) * | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| US9574005B2 (en) * | 2011-07-19 | 2017-02-21 | Chugai Seiyaku Kabushiki Kaisha | Stable Protein-containing preparation containing argininamide or analogous compound thereof |
| US20150239970A1 (en) | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| CA2898262A1 (en) * | 2013-01-24 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Tnf-alpha antigen-binding proteins |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| US9762377B2 (en) | 2015-09-29 | 2017-09-12 | Cable Television Laboratories, Inc. | Hybrid full duplex communications in a radio frequency cable network |
-
2015
- 2015-05-14 TW TW104115341A patent/TWI694836B/zh active
- 2015-05-15 EP EP19185861.2A patent/EP3715371A1/en not_active Withdrawn
- 2015-05-15 ES ES15724070T patent/ES2927990T3/es active Active
- 2015-05-15 AU AU2015260758A patent/AU2015260758B2/en not_active Ceased
- 2015-05-15 BR BR112016026811A patent/BR112016026811A2/pt not_active Application Discontinuation
- 2015-05-15 KR KR1020167034853A patent/KR20170005099A/ko not_active Ceased
- 2015-05-15 CN CN201580037513.2A patent/CN106661111A/zh active Pending
- 2015-05-15 SG SG11201609622PA patent/SG11201609622PA/en unknown
- 2015-05-15 JP JP2017512461A patent/JP6707528B2/ja active Active
- 2015-05-15 WO PCT/IB2015/053602 patent/WO2015173782A1/en not_active Ceased
- 2015-05-15 EP EP20150351.3A patent/EP3719038A1/en active Pending
- 2015-05-15 EP EP15724070.6A patent/EP3143047B8/en active Active
- 2015-05-15 CA CA2949212A patent/CA2949212C/en active Active
- 2015-05-15 US US15/311,223 patent/US10556009B2/en active Active
- 2015-05-15 DK DK15724070.6T patent/DK3143047T3/da active
- 2015-05-15 MX MX2016015006A patent/MX381232B/es unknown
- 2015-05-15 MY MYPI2016704190A patent/MY185802A/en unknown
- 2015-05-15 KR KR1020227036947A patent/KR102501602B1/ko active Active
-
2016
- 2016-11-07 IL IL248802A patent/IL248802B/en active IP Right Grant
-
2018
- 2018-06-13 US US16/007,102 patent/US20180289804A1/en not_active Abandoned
-
2020
- 2020-01-07 US US16/736,042 patent/US11179463B2/en active Active
- 2020-03-02 JP JP2020035298A patent/JP7277681B2/ja active Active
-
2021
- 2021-11-05 US US17/519,606 patent/US12296007B2/en active Active
-
2025
- 2025-04-11 US US19/176,498 patent/US20250249095A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515909A5 (https=) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2015522252A5 (https=) | ||
| JP2015120706A5 (https=) | ||
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| JP2018521638A5 (https=) | ||
| JP2020518600A5 (https=) | ||
| JP2017500018A5 (https=) | ||
| JP2020518598A5 (https=) | ||
| JP2017113028A5 (https=) | ||
| JP2016529229A5 (https=) | ||
| JP2018108081A5 (https=) | ||
| JP2011528902A5 (https=) | ||
| JP2019510739A5 (https=) | ||
| JP2020524661A5 (https=) | ||
| JP2017113019A5 (https=) | ||
| JP2018535650A5 (https=) | ||
| PE20090769A1 (es) | Proteinas de union a antigenos que se unen a par-2 | |
| JP2016539096A5 (https=) | ||
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| JP2020509031A5 (https=) | ||
| JP2015536933A5 (https=) | ||
| JP2018536393A5 (https=) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos |